2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
June 24th 2022
Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.
June 15th 2022
The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.
June 13th 2022
Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.
June 12th 2022
The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.
June 11th 2022
The first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab demonstrated deep and durable responses in patients with relapsed/refractory large B-cell lymphoma.
June 10th 2022
Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.
June 8th 2022
The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.
June 6th 2022
Patritumab deruxtecan exhibited promising clinical activity in heavily pretreated patients with advanced non-small cell lung cancer without EGFR-activating mutations, including activity in patients with other identified driver genomic alterations.
June 5th 2022
Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.
June 4th 2022
First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.
May 31st 2022
Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).
May 27th 2022
Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.
May 26th 2022
Increased spending on state public welfare programs was associated with a higher 5-year overall survival rate among Black patients.
May 24th 2022
Amplification of murine double minute 2 represents a promising target to access the so-called cellular gatekeeper p53 protein in human cancers.
May 20th 2022
For decades in cancer care, the compiling of patient-reported outcomes was limited to simple standardized questionnaires completed with pen and paper.
May 18th 2022
The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
May 16th 2022
TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in urothelial cancer and variant histology bladder cancer.
May 16th 2022
The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.
May 14th 2022
According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.
May 12th 2022
Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.